Table of Content

1. Market Introduction and Scope
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. Executive Insights and Key Takeaways
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Drug Type
2.4. Snippet by Indication
2.5. Snippet by Mode of Prescription
2.6. Snippet by Distribution Channel
3. Dynamics
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Prevalence of Chronic Pain Conditions
3.1.1.2. Rising Development of Novel Drugs
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Side Effects Associated with the Drugs
3.1.2.2. Competition from Alternative Pain Management Drugs Treatments
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Development of Non-Opioid Alternatives
3.1.3.2. XX
3.1.4. Impact Analysis
4. Strategic Insights and Industry Outlook
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest selling Brand
4.1.3. Market leaders with established Product
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Case Studies/Ongoing Research
4.5. North America Regulatory and Reimbursement Landscape
4.6. Porter’s Five Force Analysis
4.7. Supply Chain Analysis
4.8. Patent Analysis
4.9. SWOT Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders
5. Pain Management Drugs Market, By Drug Type
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
5.1.2. Market Attractiveness Index, By Drug Type
5.2. Non-Steroidal Anti-Inflammatory Drugs*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.2.3. Acetaminophen
5.2.4. Ibuprofen
5.2.5. Naproxen
5.2.6. Diclofenac
5.2.7. Aspirin
5.2.8. Celecoxib
5.2.9. Others
5.3. Opioids
5.3.1. Oxycodone
5.3.2. Fentanyl
5.3.3. Hydrocodone
5.3.4. Morphine
5.3.5. Codeine
5.3.6. Others
5.4. Corticosteroids
5.4.1. Prednisone
5.4.2. Dexamethasone
5.4.3. Prednisolone
5.4.4. Others
5.5. Muscle Relaxants
5.6. Anticonvulsant Drugs
5.7. Others
6. Pain Management Drugs Market, By Indication
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
6.1.2. Market Attractiveness Index, By Indication
6.2. Arthritis Pain*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Back Pain
6.4. Surgery Pain
6.5. Headaches & Migraine
6.6. Injury Pain
6.7. Cancer Pain
6.8. Fibromyalgia
6.9. Muscle Spasms
6.10. Menstrual Pain
6.11. Neuropathic Pain
6.12. Others
7. Pain Management Drugs Market, By Mode of Prescription
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Prescription
7.1.2. Market Attractiveness Index, By Mode of Prescription
7.2. Prescription-Based*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Over-the-Counter
8. Pain Management Drugs Market, By Distribution Channel
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Retail Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Hospital Pharmacies
8.4. Clinics
8.5. Online Pharmacies
8.6. Others
9. Competitive Landscape and Market Positioning
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. Company Profiles
10.1. Bayer AG*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. Kenvue
10.3. Teva Pharmaceuticals Industries Ltd.
10.4. Viatris Inc.
10.5. Pfizer Inc.
10.6. Abbott
10.7. Sun Pharmaceutical Industries Ltd.
LIST NOT EXHAUSTIVE
11. Assumption and Research Methodology
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. Appendix
12.1. About Us and Services
12.2. Contact Us